Citations

Clear

5628 citation(s) found for "Anderson, KS".

Proceedings of the Third International Conference on Recent Advances and Future Directions in Endocrine Manipulation of Breast Cancer
Come, Steven E. , Buzdar, Aman U. , Arteaga, Carlos L. , Bissell, Mina J. , Brown, Myles , Goss, Paul E. , Green, Jeffrey E., Medina, Daniel , Nicholson, Robert I., Santen, Richard J. , Hart, Carol S. , Ellis, Matthew J. , Ingle, James N. , Lee, Adrian V. , Schiff, Rachel , Brown, Myles

Mayo Clinic

Clinical Cancer Research | September 21, 2005 | Volume: 10 | Issue: 1 | Pages: 327s-330s

10.1158/1078-0432.ccr-031213 | PMID 14734487 Get It

Patterns of Gene Expression in Different Histotypes of Epithelial Ovarian Cancer Correlate with Those in Normal Fallopian Tube, Endometrium, and Colon
Marquez, Rebecca T., Baggerly, Keith, Patterson, Andrea P., Broaddus, Russell, Atkinson, E. Neely, Smith, David I., Hartmann, Lynn C. , Fishman, David A. , Whitaker, Regina S. , Bast, Robert C. , Lu, Karen H. , Liu, Jinsong , Frumovitz, Michael , Smith, David I., Berchuck, Andrew , Gershenson, David M. , Mills, Gordon B. , Bast, Robert C

Mayo Clinic

Clinical Cancer Research | September 21, 2005 | Volume: 11 | Issue: 17 | Pages: 6116-6126

10.1158/1078-0432.ccr-04-2509 | PMID 16144910 Get It

Abstract Purpose: Epithelial ovarian cancers are thought to arise from flattened epithelial cells that cover the ovarian surface or that line inclusion cysts. During malignant transformation, different histotypes arise that resemble epithelial cells from normal fallopian tube, endometrium, and intestine. This study compares gene expression in serous, endometrioid, clear cell, and mucinous ovarian cancers with that in the normal tissues that they resemble. Experimental Design: Expression of 63,000 probe sets was measured in 50 ovarian cancers, in 5 pools of normal ovarian epithelial brushings, and in mucosal scrapings from 4 normal fallopian tube, 5 endometrium, and 4 colon specimens. Using rank-sum analysis, genes whose expressions best differentiated the ovarian cancer histotypes and normal ovarian epithelium were used to determine whether a correlation based on gene expression existed between ovarian cancer histotypes and the normal tissues they resemble. Results: When compared with normal ovarian epithelial brushings, alterations in serous tumors correlated with those in normal fallopian tube (P = 0.0042) but not in other normal tissues. Similarly, mucinous cancers correlated with those in normal colonic mucosa (P = 0.0003), and both endometrioid and clear cell histotypes correlated with changes in normal endometrium (P = 0.0172 and 0.0002, respectively). Mucinous cancers displayed the greatest number of alterations in gene expression when compared with normal ovarian epithelial cells. Conclusion: Studies at a molecular level show distinct expression profiles of different histologies of ovarian cancer and support the long-held belief that histotypes of ovarian cancers come to resemble normal fallopian tube, endometrial, and colonic epithelium. Several potential molecular markers for mucinous ovarian cancers have been identified.
Translational Crossroads for Biomarkers
Bast, Robert C. , Lilja, Hans , Rimm, David L. , Fritsche, Herbert A. , Veltri, Robert W., Klee, George G., Allen, Andrew R., Gutman, Steven, Rubin, Mark A. , Hruszkewycz, Andrew M., Urban, Nicole , Gray, Joe W. , Kim, Nam , Lilja, Hans , Bast, Robert C , Rimm, David , Rubin, Mark A

Mayo Clinic

Clinical Cancer Research | September 21, 2005 | Volume: 11 | Issue: 17 | Pages: 6103-6108

10.1158/1078-0432.ccr-04-2213 | PMID 16144908 Get It

Abstract A group of investigators met at a Specialized Programs of Research Excellence Workshop to discuss key issues in the translation of biomarker discovery to the development of useful laboratory tests for cancer care. Development and approval of several new markers and technologies have provided informative examples that include more specific markers for prostate cancer, more sensitive tests for ovarian cancer, more objective analysis of tissue architecture and an earlier indication of response to treatment in breast cancer. Although there is no clear paradigm for biomarker development, several principles are clear. Marker development should be driven by clinical needs, including early cancer detection, accurate pretreatment staging, and prediction of response to treatment, as well as monitoring disease progression and response to therapy. Development of a national repository that uses carefully preserved, well-annotated tissue specimens will facilitate new marker development. Reference standards will be an essential component of this process. Both hospital-based and commercial laboratories can play a role in developing biomarkers from discovery to test validation. Partnering of academe and industry should occur throughout the process of biomarker development. The National Cancer Institute is in a unique position to bring together academe, industry, and the Food and Drug Administration to (a) define clinical needs for biomarkers by tumor type, (b) establish analytic and clinical paradigms for biomarker development, (c) discuss ways in which markers from different companies might be evaluated in combination, (d) establish computational methods to combine data from multiple biomarkers, (e) share information regarding promising markers developed in National Cancer Institute–supported programs, and (f) exchange data regarding new platforms and techniques that can accelerate marker development.
YKL-40 Expression is Associated with Poorer Response to Radiation and Shorter Overall Survival in Glioblastoma
Pelloski, Christopher E., Mahajan, Anita , Chang, Eric L. , Woo, Shiao Y. , Colman, Howard , Ledoux, Alicia A., Blair, Hilary, Passe, Sandra, Jenkins, Robert B. , Aldape, Kenneth , Maor, Moshe , Gilbert, Mark R. , Colman, Howard , Yang, Helen

Mayo Clinic

Clinical Cancer Research | September 21, 2005 | Volume: 11 | Issue: 9 | Pages: 3326-3334

10.1158/1078-0432.ccr-04-1765 | PMID 15867231 Get It

Abstract Purpose: YKL-40 is a secreted protein that has been reported to be overexpressed in epithelial cancers and gliomas, although its function is unknown. Previous data in a smaller sample set suggested that YKL-40 was a marker associated with a poorer clinical outcome and a genetically defined subgroup of glioblastoma. Here we test these findings in a larger series of patients with glioblastoma, and in particular, determine if tumor YKL-40 expression is associated with radiation response. Experimental Design: Patients (n = 147) with subtotal resections were studied for imaging-assessed changes in tumor size in serial studies following radiation therapy. An additional set (n = 140) of glioblastoma patients who underwent a gross-total resection was tested to validate the survival association and extend them to patients with minimal residual disease. Results: In the subtotal resection group, higher YKL-40 expression was significantly associated with poorer radiation response, shorter time to progression and shorter overall survival. The association of higher YKL-40 expression with poorer survival was validated in the gross-total resection group. In multivariate analysis with both groups combined (n = 287), YKL-40 was an independent predictor of survival after adjusting for patient age, performance status, and extent of resection. YKL-40 expression was also compared with genetically defined subsets of glioblastoma by assessing epidermal growth factor receptor amplification and loss at chromosome 10q, two of the common recurring aberrations in these tumors, using fluorescent in situ hybridization. YKL-40 was significantly associated with 10q loss. Conclusions: The findings implicate YKL-40 as an important marker of therapeutic response and genetic subtype in glioblastomas and suggest that it may play an oncogenic role in these tumors.
Gene Expression Profiles Predict Early Relapse in Ovarian Cancer after Platinum-Paclitaxel Chemotherapy
Hartmann, Lynn C. , Lu, Karen H. , Linette, Gerald P. , Cliby, William A. , Kalli, Kimberly R., Bast, Robert C. , Stec, James , Iartchouk, Natalia, Smith, David I., Hoersch, Sebastian, Shridhar, Viji , Lillie, James W., Clark, Edwin, Damokosh, Andrew I., Gershenson, David M. , Smith, David I., Ross, Jeffrey S. , Kaufmann, Scott H. , Bast, Robert C

Mayo Clinic

Clinical Cancer Research | September 21, 2005 | Volume: 11 | Issue: 6 | Pages: 2149-2155

10.1158/1078-0432.ccr-04-1673 | PMID 15788660 Get It

Abstract Purpose: Women with advanced epithelial ovarian cancer are routinely treated with platinum-paclitaxel chemotherapy following cytoreductive surgery, yet only ∼20% achieve long-term disease-free survival. We hypothesized that differences in gene expression before treatment could distinguish patients with short versus long time to recurrence after administration of platinum-paclitaxel combination chemotherapy. Experimental Design: To test this hypothesis, gene expression profiling of 79 primary surgically resected tumors from women with advanced-stage, high-grade epithelial ovarian cancer was done using cDNA microarrays containing 30,721 genes. Supervised learning algorithms were applied in an effort to develop a binary classifier that could discriminate women at risk for early (≤21 months) versus late (>21 months) relapse after initial chemotherapy. Results: A 14-gene predictive model was developed using a set of training samples (n = 51) and subsequently tested using an independent set of test samples (n = 28). This model correctly predicted the outcome of 24 of the 28 test samples (86% accuracy) with 95% positive predictive value for early relapse. Conclusions: Predictive markers for early recurrence can be identified for platinum-paclitaxel combination chemotherapy in primary ovarian carcinoma. The proposed 14-gene model requires further validation.
High CD46 Receptor Density Determines Preferential Killing of Tumor Cells by Oncolytic Measles Virus
Anderson, Bambi D., Nakamura, Takafumi , Peng, Kah-Whye , Russell, Stephen J.

Mayo Clinic

Cancer Research | September 20, 2005 | Volume: 64 | Issue: 14 | Pages: 4919-4926

10.1158/0008-5472.can-04-0884 | PMID 15256464 Get It

AbstractLive attenuated Edmonston B strain of measles virus (MV-Edm) is a potent and specific oncolytic agent, but the mechanism underlying its tumor selectivity is unknown. The virus causes cytopathic effects (CPEs) of extensive syncytial formation in tumor cells but minimal damage or cell killing in normal cells. The CPE is dependent on expression of viral proteins and the presence of CD46, the major cellular receptor of MV-Edm. Using a virally encoded soluble marker peptide to provide a quantitative readout of the level of viral gene expression, we determined that tumor cells and normal cells expressed comparable levels of viral proteins. CD46 mediates virus attachment, entry, and virus-induced cell-to-cell fusion. Using engineered cells expressing a range of CD46 densities, we determined that whereas virus entry increased progressively with CD46 density, cell fusion was minimal at low receptor densities but increased dramatically above a threshold density of CD46 receptors. It is well established that tumor cells express abundant CD46 receptors on their surfaces compared with their normal counterparts. Thus, at low CD46 densities typical of normal cells, infection occurs, but intercellular fusion is negligible. At higher densities typical of tumor cells, infection leads to extensive cell fusion. Intercellular fusion also results in enhancement of viral gene expression through recruitment of neighboring uninfected cells into the syncytium, further amplifying the CPE. Discrimination between high and low CD46 receptor density provides a compelling basis for the oncolytic specificity of MV-Edm and establishes MV-Edm as a promising CD46-targeted cancer therapeutic agent.
Fruits and Vegetables and Ovarian Cancer Risk in a Pooled Analysis of 12 Cohort Studies
Koushik, Anita , Anderson, Kristin E. , Arslan, Alan A. , Brandt, Piet A. van den , Buring, Julie E. , Cerhan, James R. , Colditz, Graham A. , Fraser, Gary E. , Freudenheim, Jo L. , Goldbohm, R. Alexandra, Hankinson, Susan E. , Koenig, Karen L. , Larsson, Susanna C. , Leitzmann, Michael F. , McCullough, Marjorie L. , Miller, Anthony B. , Patel, Alpa V. , Rohan, Thomas E. , Schatzkin, Arthur, Smit, Ellen, Zhang, Shumin M., Smith‐Warner, Stephanie A. , Hunter, David J. , Spiegelman, Donna , Beeson, W. Lawrence , Genkinger, Jeanine M. , Hankinson, Susan E. , Willett, Walter C. , Wolk, Alicja , Cerhan, James R , Koushik, Anita , Arslan, Alan A , Colditz, Graham A , Larsson, Susanna C , McCullough, Marjorie L

Mayo Clinic

Cancer Epidemiology, Biomarkers & Prevention | September 20, 2005 | Volume: 14 | Issue: 9 | Pages: 2160-2167

10.1158/1055-9965.epi-05-0218 | PMID 16172226 Get It

AbstractBecause fruits and vegetables are rich in bioactive compounds with potential cancer-preventive actions, increased consumption may reduce the risk of ovarian cancer. Evidence on the association between fruit and vegetable intake and ovarian cancer risk has not been consistent. We analyzed and pooled the primary data from 12 prospective studies in North America and Europe. Fruit and vegetable intake was measured at baseline in each study using a validated food-frequency questionnaire. To summarize the association between fruit and vegetable intake and ovarian cancer, study-specific relative risks (RR) were estimated using the Cox proportional hazards model, and then combined using a random-effects model. Among 560,441 women, 2,130 cases of invasive epithelial ovarian cancer occurred during a maximum follow-up of 7 to 22 years across studies. Total fruit intake was not associated with ovarian cancer risk—the pooled multivariate RR for the highest versus the lowest quartile of intake was 1.06 [95% confidence interval (95% CI), 0.92-1.21; P value, test for trend = 0.73; P value, test for between-studies heterogeneity = 0.74]. Similarly, results for total vegetable intake indicated no significant association (pooled multivariate RR, 0.90; 95% CI, 0.78-1.04, for the highest versus the lowest quartile; P value, test for trend = 0.06; P value, test for between-studies heterogeneity = 0.31). Intakes of botanically defined fruit and vegetable groups and individual fruits and vegetables were also not associated with ovarian cancer risk. Associations for total fruits and vegetables were similar for different histologic types. These results suggest that fruit and vegetable consumption in adulthood has no important association with the risk of ovarian cancer.
Automated Spectrophotometric Analysis of Mitochondrial Respiratory Chain Complex Enzyme Activities in Cultured Skin Fibroblasts
Kramer, Karen A., Oglesbee, Devin , Hartman, Stacy, Huey, Joe, Anderson, Bambi D., Magera, Mark J , Matern, Dietrich , Rinaldo, Piero, Robinson, Brian H., Cameron, Jessie M. , Hahn, Si Houn , Oglesbee, Devin

Mayo Clinic

Clinical Chemistry | September 3, 2005 | Volume: 51 | Issue: 11 | Pages: 2110-2116

10.1373/clinchem.2005.050146 | PMID 16141288 Get It

Abstract Background: Mitochondrial respiratory chain complex (RCC) disorders may occur as commonly as 1 in 8500 individuals. Because of the great variability of phenotypic presentations, measurement of individual RCC enzyme activities is a crucial diagnostic process. Current assay methods are time-consuming and labor-intensive and thus constitute a major impediment to clinical practice. A method with a faster turnaround time would therefore be beneficial. Method: We developed an automated spectrophotometric method for measuring the respiratory chain enzyme activities of complex I, complex II + III, and complex IV with the Hitachi 912, an automated spectrophotometer. Mitochondrial citrate synthase was also determined for normalization of the RCC activities. Results: A blinded method comparison with samples from an external testing center yielded a 91% concordance of interpretations. Mean intraassay imprecision (as CV; n = 20) in a single batch analysis of each RCC was 5.9%. Interassay imprecision, evaluated on 2 samples harvested and analyzed 3 times each, gave mean CVs of 10%–18%. Conclusions: With this automated method, a panel of RCC enzyme activities can be determined in <2 h. In addition, an immunoblot assay using monoclonal antibodies against specific subunits of RCC enzyme complexes can be informative in cases of borderline enzyme activity. Our results suggest that in vitro diagnosis of RCC enzyme deficiencies in skin fibroblasts is an effective alternative to invasive muscle biopsy.
To Feed or Not to Feed: Is That the Right Question?
Moynihan, Timothy J. , Kelly, Darlene G., Fisch, Michael

Mayo Clinic

Journal of Clinical Oncology | August 31, 2005 | Volume: 23 | Issue: 25 | Pages: 6256-6259

10.1200/jco.2005.04.019 | PMID 16135494 Get It

Designers don't hurt people; designs do
Anderson, Douglas W.

Mayo Clinic

Interactions | August 3, 2005 | Volume: 12 | Issue: 4 | Pages: 60-61

10.1145/1070960.1070992 Get It

How many people do you know who have physical problems they attribute to computer use? (I wear wrist braces at night myself, so that my mild carpal-tunnel syndrome doesn't bother me much during the day.) Many of us seem to have the impression that such problems arise mainly from poor hardware design... or perhaps from an overindulgence in gaming, with its incessant, repetitive arm/wrist/hand/finger movements. But is it that simple? In this Whiteboard column, Doug Anderson points out how interaction design and usability efforts can overlook such problems, and urges us to pay more attention to them. I would add one more suggestion to his list of ideas: Even when longitudinal usability testing is not feasible, we can monitor our applications and systems in long-term use and note any physical problems that tend to appear among our users. ---Elizabeth Buie